MedTrace Logo

The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome

NCT02431533 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-06-12

Study results available
· View outcomes & findings →

Summary

IBS is a disorder of movement in the gut. People who have IBS may have diarrhea, constipation, or alternating bouts of both. IBS is not caused by injury or illness. Often the only way doctors can diagnose it is to rule out other conditions through testing.

Conditions

  • Irritable Bowel Syndrome With Diarrhea

Interventions

DIETARY_SUPPLEMENT

PX0612

PX0612 is a probiotic contained in a veggie capsule.

DIETARY_SUPPLEMENT

Di-Calcium Phosphate

Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate

Sponsors & Collaborators

  • University of Alberta

    collaborator OTHER

  • Pharmabiotix Inc

    lead INDUSTRY

Principal Investigators

  • Lawrence Richer · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02431533 on ClinicalTrials.gov